

Supplementary Table 1. Comparison of Patients with HCVr and Hepatitis Flare to Those with HCVr and without Hepatitis Flare.

Characteristic	No. (%) of Patients	No. (%) of Patients	<i>P</i>
	with HCVr and Hepatitis Flare (n = 10)	with HCVr without Hepatitis Flare (n=13)	
Age in years, median (IQR)	57 (55-69)	61 (53-63)	0.95
Sex, male	8 (80)	10 (77)	>0.99
Race			
White	8 (80)	8 (62)	0.40
Black	0	5 (38)	0.04
Hispanic	1 (10)	0	0.43
Asian	1 (10)	0	0.43
Type of cancer, hematologic cancers	8 (80)	10 (77)	>0.99
HCV genotype			
1	5 (50)	12 (92)	0.05
2	4 (40)	0	0.02
4	0	1 (8)	>0.99
6	1 (10)	0	>0.99
rs12979860 genotype*			
CC	5/8 (63)	2/9 (22)	0.15
CT	2/8 (25)	6/9 (67)	0.15
TT	1/8 (13)	1/9 (11)	>0.99
Cirrhosis	0	4 (31)	0.10
Liver fibrosis			

Liver biopsy, Metavir score F3-F4	1/5 (20)	1/8 (12)	>0.99
Hematopoietic cell transplant	0	3 (23)	0.22
Drugs received			
Rituximab containing	4 (40)	6 (46)	>0.99
High dose steroids	6 (60)	7 (54)	>0.99
Alkylating agents [†]	3 (30)	6 (46)	0.66
Platinum [‡]	2 (20)	1 (8)	0.56
Antimetabolite [§]	5 (50)	6 (46)	>0.99
Anthracyclin [¶]	3 (30)	1 (8)	0.28
Topoisomerase	2 (20)	0	0.17
Mitotic inhibitor ^{**}	2 (20)	1 (8)	0.56
Monoclonal Antibody ^{††}	2 (20)	5 (39)	0.40
Tacrolimus	1 (10)	0	0.43
HCV RNA (log10IU/mL)			
Baseline HCV RNA, median (IQR)	5.8 (5.1 - 6.2)	6.0 (5.3 - 6.3)	0.66
Peak RNA, median (IQR)	7.4 (6.9 - 7.7)	7.1 (6.7 - 7.6)	0.42
Change RNA, median (IQR)	1.6 (1.0 - 2.1)	1.2 (1.0 - 1.5)	0.29
Absolute lymphocyte count (cells/ μ L)			
Nadir lymphocyte, median (IQR)	240 (20 - 730)	310 (50 - 550)	0.95
Drop of Lymphocyte, median (IQR)	1140 (330 - 1650)	1110 (750 - 1680)	0.49
Duration of Lymphopenia, median (IQR)	124 (26 - 205)	53 (5 - 199)	0.49
<u>Baseline ALT (IU/mL)</u>	<u>87 (71-120)</u>	<u>56 (29-75)</u>	<u>0.004</u>

Abbreviations: HCVr, HCV reactivation; HbcAb, hepatitis B core antibody; HbsAg, hepatitis B surface antigen;

IQR, interquartile range;

*Formerly known as Interleukin-28B.

†Cyclophosphamide, ifosfamide, melphalan, bendamustine, or busulfan.

‡Cisplatin, carboplatin, or oxalaplatin.

§Fluorouracil, capecitabine, cytarabine, gemcitabine, decitabine, Mercaptopurine, fludarabine, cladribine, clofarabine, methotrexate, or pemetrexed.

¶Daunorubicin, doxorubicin, epirubicin, idarubicin, or bleomycin.

||Topotecan, etoposide, or irinotecan.

**Paclitaxel, docetaxel, vinblastine, or vincristine.

††Cetuximab, ruxolitinib, trastuzumab, bortezomib, carfilzomib, bevacizumab, dasatinib, ipilimumab, dabrafenib, trametinib, vismodegib, alemtuzumab, ofatumumab, pazopanib, or regorafenib.

Supplementary Figure 1. Correlation between changes in HCV-RNA and ALT.

